Flossbach Von Storch AG Raises Position in BioNTech SE (NASDAQ:BNTX)

Flossbach Von Storch AG lifted its stake in shares of BioNTech SE (NASDAQ:BNTX) by 1.0% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 3,548,660 shares of the company’s stock after buying an additional 35,445 shares during the quarter. BioNTech accounts for approximately 1.7% of Flossbach Von Storch AG’s holdings, making the stock its 19th largest holding. Flossbach Von Storch AG’s holdings in BioNTech were worth $374,526,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of BNTX. Rakuten Securities Inc. acquired a new position in shares of BioNTech in the fourth quarter worth about $134,000. Slow Capital Inc. boosted its stake in shares of BioNTech by 15.7% during the 4th quarter. Slow Capital Inc. now owns 29,526 shares of the company’s stock valued at $3,116,000 after buying an additional 4,012 shares during the last quarter. Mackenzie Financial Corp grew its position in shares of BioNTech by 326.3% during the fourth quarter. Mackenzie Financial Corp now owns 21,874 shares of the company’s stock worth $2,303,000 after buying an additional 16,743 shares in the last quarter. Perigon Wealth Management LLC increased its stake in shares of BioNTech by 40.5% in the fourth quarter. Perigon Wealth Management LLC now owns 4,505 shares of the company’s stock worth $476,000 after buying an additional 1,299 shares during the last quarter. Finally, Custom Index Systems LLC acquired a new stake in BioNTech in the fourth quarter valued at $522,000. 15.52% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the stock. The Goldman Sachs Group dropped their target price on shares of BioNTech from $113.00 to $100.00 and set a “neutral” rating for the company in a research report on Wednesday, February 28th. UBS Group cut their price objective on BioNTech from $110.00 to $101.00 and set a “neutral” rating on the stock in a research note on Wednesday, March 27th. JPMorgan Chase & Co. decreased their target price on BioNTech from $99.00 to $90.00 and set an “underweight” rating for the company in a research report on Friday, March 22nd. HC Wainwright reissued a “buy” rating and set a $107.00 price target on shares of BioNTech in a research report on Wednesday. Finally, BMO Capital Markets decreased their price objective on shares of BioNTech from $127.00 to $123.00 and set an “outperform” rating for the company in a report on Thursday, March 21st. One research analyst has rated the stock with a sell rating, five have given a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $120.40.

BioNTech Stock Performance

NASDAQ:BNTX traded up $0.06 during mid-day trading on Wednesday, hitting $86.40. The stock had a trading volume of 1,264,662 shares, compared to its average volume of 671,486. BioNTech SE has a 52 week low of $85.21 and a 52 week high of $125.83. The company has a current ratio of 9.43, a quick ratio of 9.26 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $20.54 billion, a price-to-earnings ratio of 20.97 and a beta of 0.23. The company has a 50 day simple moving average of $91.49 and a 200-day simple moving average of $97.57.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings data on Wednesday, March 20th. The company reported $2.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.64 by ($0.59). BioNTech had a return on equity of 4.60% and a net margin of 24.26%. The business had revenue of $1.59 billion during the quarter, compared to the consensus estimate of $2.04 billion. On average, research analysts expect that BioNTech SE will post -1.67 earnings per share for the current fiscal year.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.